NLA Resources
Sodium-Glucose Co-Transporter 2 Inhibitors (SGLTI2i)
3 Resources
Knowledge Center
The National Lipid Association is your destination for the science of lipid medicine. Now, everything we know is in one place.
Sodium-Glucose Co-Transporter 2 Inhibitors (SGLTI2i)
3 Available Resources
Case Study: Role of Sodium-Glucose Cotransporter 2 Inhibitors in Managing Residual Cardiovascular Risk
The following case involves a 58-yearold gentleman with a history of complex cardiovascular disease and several cardiometabolic risk factors as…
Non-Lipid Lowering Therapies Impacting Cardiovascular Disease Risk
Atherosclerosis is the leading cause of death and disability globally, with the highest burden continuing to have dominant impact in…
The Impact of Sodium-Glucose Co-Transporter 2 Inhibitors on Lipid Profile
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are novel, effective oral anti-hyperglycemic medications that inhibit glucose reabsorption in the proximal convoluted tubule…
Join the NLA
Become A Member
When you become a member of the NLA, you become part of a collegial multidisciplinary group of leaders dedicated to improving lipid and cardiometabolic health.
